ArticleFrontiers in immunology2025
Angiotensinogen and C3 compete for renin-induced complement activation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement C3 in panvascular disease: a central integrator of immune signaling and vascular remodeling.Clinical science (London, England : 1979) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renin from plasma, kidney, and recombinant sources was previously demonstrated to cleave C3 to C3a and C3b. C3a was generated at a similar rate to that by C3 convertase, and C3 cleavage was inhibited by the renin inhibitor aliskiren. Renin endogenously produced by Calu6 cells also led to C3 deposition on cells. These results have been challenged by another group suggesting that recombinant renin does not cleave C3 or that renin was contaminated by trypsin, which also cleaves C3. Here, we investigated C3 cleavage by recombinant renin and competitive inhibition in the presence of angiotensinogen. Recombinant renin was analyzed by mass spectrometry using endopeptidase LysC digestion and did not contain trypsin. C3 cleavage, using our protocol and that of the other group, showed cleavage to C3b by immunoblotting. Cleavage was inhibited by aliskiren, which inhibits renin but not trypsin. Cleavage to C3a occurred within 1 min as detected by enzyme-linked immunosorbent assay (ELISA). Angiotensinogen competed for renin-mediated C3 cleavage and inhibited C3a generation, but C3 did not inhibit cleavage of angiotensinogen to angiotensin I (detected by ELISA). The results suggest that renin cleaves C3 but angiotensinogen is its preferred substrate. The interaction between renin and C3 may gain importance in the kidney where renin concentrations are considerably higher than in the circulation and when the primary substrate, angiotensinogen, is cleaved and thereby depleted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.